Take our survey

We value your opinion. To improve your experience on emend.com, we are conducting research to better understand the needs of our visitors.

Please take a few moments to complete a short 5-question survey.

Please be assured that this survey is for research purposes only and that your privacy will be respected. Your responses will remain strictly confidential.

Any data collected in this survey will be handled in accordance with the privacy policy of Vovici, who is administering this survey on behalf of Merck.

Your responses to this survey will be kept strictly confidential and WILL NOT be used to contact you or sell you products or information.

This survey is sponsored by Merck.

Take now Take later No thanks
EMEND (aprepitant) Information

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
Merck

In combination with a 5-HT3 receptor antagonist and a corticosteroid, EMEND can be used in a wide range of patients receiving chemotherapy.

EMEND, in combination with other antiemetic agents, is indicated for prevention of:

  • Acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy, including high-dose cisplatin.
  • Nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy.
Consider EMEND to help prevent CINV beginning with the first cycle of chemotherapy

Selected Important Risk Information

EMEND, when administered orally, is a moderate cytochrome P450 isoenzyme 3A4 (CYP3A4) inhibitor. Because fosaprepitant is rapidly converted to aprepitant, neither drug should be used concurrently with pimozide, terfenadine, astemizole, or cisapride. Inhibition of CYP3A4 by aprepitant could result in elevated plasma concentrations of these drugs, potentially causing serious or life-threatening reactions.

Before prescribing EMEND or EMEND for Injection, please read the Prescribing Information. The Patient Information also is available.

For information about Merck products or services, please call 866-448-7590. The Merck National Service Center will be pleased to assist you Monday through Friday from 8 AM to 7 PM ET.

20950402(6)-07/09-EME